315 studies found for:    biogen | biogen
Show Display Options
Rank Status Study
21 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
22 Not yet recruiting Gastrointestinal Tolerability Study Of Dimethyl Fumarate (DMF) In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: BG00012
23 Recruiting Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Biological: BG00002 (Natalizumab);   Drug: Placebo
24 Withdrawn BIIB014 Phase 2a Monotherapy
Condition: Parkinson's Disease
Interventions: Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;   Drug: placebo
25 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)
26 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
27 Not yet recruiting Real-world Outcomes on Tecfidera® (BG00012, Dimethyl Fumarate) Post-Tysabri® (BG00002, Natalizumab)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BG00002 (Natalizumab);   Drug: BG00012 (dimethyl fumarate)
28 Recruiting Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
Condition: Relapsing Forms of Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
29 Not yet recruiting Immunogenicity and Safety Study of Natalizumab (BG00002) Administered to Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
30 Recruiting BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Subjects With Painful Lumbar Radiculopathy
Conditions: Painful Lumbar Radiculopathy;   Sciatica;   Radiculopathy
Interventions: Drug: BG00010;   Drug: Placebo
31 Not yet recruiting Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate (DMF)-Treated Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Drug: Acetylsalicylic acid;   Drug: ASA-Placebo
32 Recruiting SFERA Study: Prospective, Single-arm, Open-label, Multi-center, Interventional Phase IV Study
Conditions: Relapsing-Remitting Multiple Sclerosis;   Clinical Isolated Syndrome (CIS);   Multiple Sclerosis
Intervention: Device: Interferon-beta-1a
33 Not yet recruiting Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With BG00012 or Standard of Care
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Other: Standard of Care (SOC) First Line Treatements
34 Not yet recruiting A Phase 3b Study of BG00012's Effect on Vaccination Response in Subjects With Relapsed Forms of Multiple Sclerosis
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Biological: Td (tetanus diphtheria toxoids);   Biological: Pneumococcal Vaccine;   Biological: KLH (Keyhole limpet hemocyanin)
35 Not yet recruiting Pilot Tape Harvesting Study
Conditions: Healthy;   Lupus Erythematosus, Discoid
Interventions: Procedure: Skin Taping;   Procedure: Blood Sampling;   Procedure: Skin Biopsy
36 Recruiting Dimethyl Fumarate (DMF) Observational Study
Condition: Multiple Sclerosis
Intervention:
37 Not yet recruiting A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Conditions: Systemic Lupus Erythematosus;   Healthy
Interventions: Drug: BIIB059;   Drug: Placebo
38 Recruiting Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
Condition: Healthy
Interventions: Drug: BIIB061;   Drug: Placebo;   Drug: 14C-BIIB061
39 Recruiting Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
Condition: Progressive Multifocal Leukoencephalopathy
Intervention:
40 Terminated How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1a

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years